Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $84.67, for a total value of $423,350.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $85.42 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $39.21 and a fifty-two week high of $91.82. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same quarter in the previous year, the company earned ($0.51) EPS. analysts anticipate that Neurocrine Biosciences, Inc. will post -0.19 EPS for the current year.
A number of equities research analysts have weighed in on NBIX shares. Citigroup reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BMO Capital Markets lifted their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Deutsche Bank reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Oppenheimer lifted their target price on Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $90.79.
TRADEMARK VIOLATION NOTICE: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/insider-selling-neurocrine-biosciences-inc-nbix-director-sells-423350-00-in-stock/1907365.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.